Antiplatelet therapy following transcatheter XXXX .

@entity1 @entity1187 @entity64 @entity548 @entity1397 @entity117 @entity886
OBJECTIVE: There is limited evidence to support decision making on antiplatelet therapy following transcatheter @entity886 (TAVI). Our aim was to assess the efficacy and safety of @entity117 -only (ASA) versus dual antiplatelet therapy (DAPT) following TAVI. METHODS: We performed a systematic review and pooled analysis of individual @entity1 data from 672 @entity1 comparing single versus DAPT following TAVI. Primary endpoint was defined as the composite of net adverse clinical and cerebral events (NACE) at 1   month, including all-cause mortality, @entity1187 ( @entity1187 ), @entity64 , life-threatening and major @entity548 . RESULTS: At 30   days a NACE rate of 13% was observed in the ASA-only and in 15% of the DAPT group (OR 0.83, 95% CI 0.48 to 1.43, p=0.50). A tendency towards less life-threatening and major @entity548 was observed in @entity1 treated with ASA (OR 0.56, 95% CI 0.28 to 1.11, p=0.09). Also, ASA was not associated with an increased all-cause mortality (OR 0.91, 95% CI 0.36 to 2.27, p=0.83), @entity1187 (OR 0.5, 95% CI 0.05 to 5.51, p=0.57) or @entity64 (OR 1.21; 95% CI 0.36 to 4.03, p=0.75). CONCLUSIONS: No difference in 30-day NACE rate was observed between ASA-only or DAPT following TAVI. Moreover, a trend towards less life-threatening and major @entity548 was observed in favour of ASA. Consequently the additive value of @entity1397 warrants further investigation.
